Cure8 research brief
Improving oral delivery and colon targeting of probiotics could make probiotic therapies more effective for ulcerative colitis by increasing survival through the gut and retention at inflamed sites. If translated to humans, such technology might increase the impact of probiotic-based treatments.
Researchers and clinicians working on IBD therapies, drug-delivery or microbiome interventions; adult patients interested in probiotic research and new treatment approaches.
This abstract reports a preclinical delivery-technology study testing a multi-layer coated porous microsphere that carries Lactobacillus reuteri for oral treatment of ulcerative colitis.
The coating includes a metal–polyphenol network and chitosan/hyaluronate polysaccharide layers designed to protect probiotics through the stomach, target inflamed colon tissue, and release bacteria in response to transferrin and acid conditions.
In DSS-induced mouse models of acute colitis the formulation improved probiotic survival and colonic retention (reported up to 72 hours), reduced inflammation markers (IL-6, IL-1β, TNF-α), increased IL-10, preserved mucin and tight junction proteins, and altered the gut microbiota toward more Lactobacillus species.
The authors report good in vivo safety in the study. This is a laboratory and animal-model study (abstract-level summary provided by the journal). It describes a delivery platform and biological effects in mice rather than a completed clinical trial in people, so clinical benefits in patients remain unproven.
This is an abstract-level report of preclinical (mouse) experiments published in a pharmaceutics journal. Animal-model efficacy and safety do not guarantee similar results in humans; further development, toxicity testing, and clinical trials would be needed.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study suggests a traditional Chinese medicine formula can reduce disease signs in a mouse model of chronic relapsing ulcerative colitis and that its effects are mediated by changes in the gut microbiota and microbial...
The article explains how gut bacteria may contribute to IBD and summarizes common tests and treatments people are likely to encounter. It highlights emerging microbial therapies (probiotics and FMT) that some patients...
If successful, this approach could lower costs and simplify storage/transport of an established IBD antibody (adalimumab) and enable oral delivery, which would be relevant to people with Crohn’s disease or ulcerative...
